Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
    Meeting Abstract

    Mezquita, L.; Arbour, K.; Auclin, E.; Saravia, D.; Rizvi, H.; Hendriks, L.; Planchard, D.; Park, W.; Nadal, E.; Ruffinelli Rodriguez, J. C.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
    Meeting Abstract

    Stacchiotti, S.; Blay, J. Y.; Jones, R. L.; Demetri, G. D. D.; Mir, O.; Italiano, A.; Thomas, D.; Chen, T. W. W.; Schöffski, P.; Gil, T.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D.; Choueiri, T. K.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study
    Meeting Abstract

    George, D. J.; Figlin, R.; Motzer, R. J.; Paty, J.; Lechuga Frean, M. J.; Zanotti, G.; Bhattacharyya, H.; Ramaswamy, K.; Deannuntis, L.; Ravaud, A.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
    Meeting Abstract

    Rosenberg, J.; Necchi, A.; Sweis, R. F.; Nakajima, K.; Lu, C.; Nogai, H.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914)
    Meeting Abstract

    Bex, A.; Grünwald, V.; Russo, P.; Tomita, Y.; Berghorn, E.; McHenry, M. B.; Motzer, R. J.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
    Meeting Abstract

    Ho, A. L.; Chau, N.; Bauman, J.; Bible, K.; Chintakuntlawar, A.; Cabanillas, M. E.; Wong, D. J.; Garcia, I. B.; Brose, M. S.; Boni, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer
    Meeting Abstract

    Ott, P. A.; Govindan, R.; Naing, A.; Friedlander, T. W.; Margolin, K.; Lin, J. J.; Bhardwaj, N.; Hellman, M. D.; Srinivasan, L.; Greshock, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Chowdhury, S.; McDermott, R.; Piulats, J. M.; Shapiro, J. D.; Mejlholm, I.; Morris, D.; Ostler, P.; Hussain, A.; Dumbadze, I.; Goldfischer, E. R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)
    Meeting Abstract

    Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M. E.; Halabi, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save